Budget Amount *help |
¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Outline of Final Research Achievements |
Epigenetic modifications such as histone deacetylation are commonly related to tumor development and histone deacetylase (HDAC) inhibitors have been shown to be potential drugs for cancer treatment. Ky-2 is a novel HDAC inhibitor produced by a combination of the HDAC inhibitors TSA and TPX. In the present study, we investigated the effectiveness of Ky-2 to induce cell cycle and apoptosis in oral squamous carcinoma cells. In addition, we examined the signaling pathway related to the cell cycle and apoptosis in Ky-2-treated oral squamous carcinoma cells.
|